Brokerages expect that Gilead Sciences, Inc. (NASDAQ:GILD) will post $5.37 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Gilead Sciences’ earnings. The highest sales estimate is $5.64 billion and the lowest is $5.05 billion. Gilead Sciences posted sales of $6.51 billion in the same quarter last year, which suggests a negative year over year growth rate of 17.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Gilead Sciences will report full year sales of $5.37 billion for the current year, with estimates ranging from $20.31 billion to $21.63 billion. For the next financial year, analysts forecast that the firm will report sales of $20.95 billion per share, with estimates ranging from $19.04 billion to $22.18 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period in the prior year, the business posted $2.70 EPS. The firm’s revenue was down 18.7% compared to the same quarter last year.
Several research analysts have commented on the stock. Mizuho upped their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, December 11th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective for the company. in a report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $87.04.
Shares of Gilead Sciences (NASDAQ GILD) opened at $80.94 on Wednesday. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. The company has a market cap of $105,415.91, a price-to-earnings ratio of 23.26, a P/E/G ratio of -1.85 and a beta of 1.22.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 2.82%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 59.77%.
In related news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 50,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the sale, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold a total of 418,333 shares of company stock worth $32,742,108 over the last three months. 1.30% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Wayne Hummer Investments L.L.C. boosted its holdings in shares of Gilead Sciences by 13.7% during the 2nd quarter. Wayne Hummer Investments L.L.C. now owns 20,286 shares of the biopharmaceutical company’s stock valued at $1,436,000 after acquiring an additional 2,450 shares during the last quarter. Boston Private Wealth LLC boosted its holdings in shares of Gilead Sciences by 2.6% during the 2nd quarter. Boston Private Wealth LLC now owns 218,512 shares of the biopharmaceutical company’s stock valued at $15,466,000 after acquiring an additional 5,591 shares during the last quarter. Truepoint Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $204,000. Tocqueville Asset Management L.P. boosted its holdings in shares of Gilead Sciences by 2.2% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 35,133 shares of the biopharmaceutical company’s stock valued at $2,487,000 after acquiring an additional 757 shares during the last quarter. Finally, Van Cleef Asset Management Inc boosted its holdings in shares of Gilead Sciences by 3.0% during the 2nd quarter. Van Cleef Asset Management Inc now owns 65,548 shares of the biopharmaceutical company’s stock valued at $4,639,000 after acquiring an additional 1,927 shares during the last quarter. 75.71% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect Gilead Sciences, Inc. (GILD) Will Post Quarterly Sales of $5.37 Billion” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/zacks-analysts-expect-gilead-sciences-inc-gild-will-post-quarterly-sales-of-5-37-billion.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Get a free copy of the Zacks research report on Gilead Sciences (GILD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.